PortfoliosLab logo
PortfoliosLab logo
Tools
Portfolios
Screeners
Discussions
ML vs. SRPT
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

ML vs. SRPT

Last updated May 21, 2025

Compare and contrast key facts about MoneyLion Inc. (ML) and Sarepta Therapeutics, Inc. (SRPT).

Scroll down to visually compare performance, riskiness, drawdowns, and other indicators and decide which better suits your portfolio: ML or SRPT.

Correlation

The correlation between ML and SRPT is 0.03, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.

Performance

ML vs. SRPT - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in MoneyLion Inc. (ML) and Sarepta Therapeutics, Inc. (SRPT). The values are adjusted to include any dividend payments, if applicable.

Loading data...

Key characteristics

Fundamentals

Market Cap

ML:

$972.40M

SRPT:

$3.73B

EPS

ML:

$0.76

SRPT:

-$2.64

PS Ratio

ML:

1.78

SRPT:

1.67

PB Ratio

ML:

3.34

SRPT:

3.26

Total Revenue (TTM)

ML:

$424.90M

SRPT:

$2.23B

Gross Profit (TTM)

ML:

$356.78M

SRPT:

$1.81B

EBITDA (TTM)

ML:

$37.39M

SRPT:

-$117.73M

Returns By Period

ML

YTD

N/A

1M

N/A

6M

N/A

1Y

N/A

3Y*

N/A

5Y*

N/A

10Y*

N/A

SRPT

YTD

-67.11%

1M

-25.66%

6M

-62.49%

1Y

-69.43%

3Y*

-17.47%

5Y*

-22.79%

10Y*

4.31%

*Annualized

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

MoneyLion Inc.

Sarepta Therapeutics, Inc.

Risk-Adjusted Performance

ML vs. SRPT — Risk-Adjusted Performance Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.
ML
The Risk-Adjusted Performance Rank of ML is 6262
Overall Rank
The Sharpe Ratio Rank of ML is 6060
Sharpe Ratio Rank
The Sortino Ratio Rank of ML is 6464
Sortino Ratio Rank
The Omega Ratio Rank of ML is 6565
Omega Ratio Rank
The Calmar Ratio Rank of ML is 6262
Calmar Ratio Rank
The Martin Ratio Rank of ML is 5959
Martin Ratio Rank
SRPT
The Risk-Adjusted Performance Rank of SRPT is 33
Overall Rank
The Sharpe Ratio Rank of SRPT is 44
Sharpe Ratio Rank
The Sortino Ratio Rank of SRPT is 44
Sortino Ratio Rank
The Omega Ratio Rank of SRPT is 22
Omega Ratio Rank
The Calmar Ratio Rank of SRPT is 33
Calmar Ratio Rank
The Martin Ratio Rank of SRPT is 11
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

ML vs. SRPT - Risk-Adjusted Performance Comparison

This table presents a comparison of risk-adjusted performance metrics for MoneyLion Inc. (ML) and Sarepta Therapeutics, Inc. (SRPT). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

No data
No data
No data
No data
No data

Loading data...

Dividends

ML vs. SRPT - Dividend Comparison

Neither ML nor SRPT has paid dividends to shareholders.

Tickers have no history of dividend payments

Drawdowns

ML vs. SRPT - Drawdown Comparison

Loading data...

Volatility

ML vs. SRPT - Volatility Comparison

Loading data...

Financials

ML vs. SRPT - Financials Comparison

This section allows you to compare key financial metrics between MoneyLion Inc. and Sarepta Therapeutics, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.

Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities

0.00200.00M400.00M600.00M800.00MJulyOctober2021AprilJulyOctober2022AprilJulyOctober2023AprilJulyOctober2024AprilJulyOctober2025
158.59M
744.86M
(ML) Total Revenue
(SRPT) Total Revenue
Values in USD except per share items